Distinguished Professor Xu-Feng Huang (right)

IHMRI researcher has identified a molecule that could hold the key to more effective drug treatments for patients with schizophrenia

Distinguished Professor Huang and his research team collaborated with counterparts in China to uncover the role of the Neural Cell Adhesion Molecule (NCAM) in connecting cells and brain development.

The discovery was recently published in the journal Schizophrenia ResearchRead the full article.

The study suggests that young patients with first episode schizophrenia had lower rates of the molecule which contributed to lower cognitive function.

Schizophrenia affects memory loss, decision making and attention span, which are symptoms that are not effectively treated by current antipsychotic medications.

Researchers hope the breakthrough will lead to clinical trials to boost levels of NCAM in schizophrenia sufferers to increase brain cognition.

It is hoped the next stage of the research will be developing a therapeutic drug.

Statistics on Schizophrenia

  • In Australia, approximately 1 in 100 people have or will develop schizophrenia during their lifetime and it is usually a life-long illness.
  • 80% of people with schizophrenia experience cognitive deficits including impaired memory, attention and decision making.
  • Schizophrenia ranks among the top 10 causes of disability in developed countries worldwide.

You may also like

John Laidlaw, Associate Professor Lezanne Ooi, Professor Justin Yerbury, Janet Nash from MND Australia, Melissa Duggan and Senior Research Assistant Natalie Farrawell
Philanthropy for motor neurone disease research at IHMRI
Associate Professor Lezanne Ooi Professor Chennupati Jagadish Photo Credit Paul Jones
IHMRI researchers receive dementia grant for ‘mini-brain’ research
Dr Martin Engel, Dr Yi Sing Gee, Associate Professor Lezanne Ooi and Dr Chris Hyland Photo credit Paul Jones
Dual action drug treatment for aggressive brain tumours